Figure 1



= SOLID SUPPORT

R = TERMINAL PROTECTING GROUP
FOR EXAMPLE:
DIMETHOXYTRITYL (DMT)

(1) = CLEAVABLE LINKER
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR INVERTED DEOXYABASIC SUCCINATE)

(2) = CLEAVABLE LINKER
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR INVERTED DEOXYABASIC SUCCINATE)



INVERTED DEOXYABASIC SUCCINATE LINKAGE



GLYCERYL SUCCINATE LINKAGE

Figure 2


6646.96
6850.04
100
90
80
70
60
50
40
30
20
10
0
% Intensity
650
4520
8390
Mass (m/z)

Figure 3


dsRNA OR 3' 3'
DICER
siRNA duplex
expressed/synthetic siRNA
Active siRNA complex
Target Recognition
RISC complex
RNA synthesis by RdRP
Additional siRNA generated by DICER (Plasterk, 2002, Science, 296, 1263-1265)
Endonuclease Cleavage of Target

Figure 4

A

SENSE STRAND (SEQ ID NO 2438)
ALL POSITIONS RIBONUCLEOTIDE EXCEPT POSITIONS (N N)

5'- B-N N N N N N N N N N N N N N N N N N N (N N)-B -3'
3'- L-(N_SN) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2439)
ALL POSITIONS RIBONUCLEOTIDE EXCEPT POSITIONS (N N)

B

SENSE STRAND (SEQ ID NO 2440)
ALL PYRIMIDINES = 2'-FLUORO AND ALL PURINES = 2'-OM EXCEPT POSITIONS (N N)

5'- N N N N N N N N N N N N N N N N N N N (N_SN) -3'
3'- L-(N_SN) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2441)
ALL PYRIMIDINES = 2'-FLUORO AND ALL PURINES = 2'-O-ME EXCEPT POSITIONS (N N)

C

SENSE STRAND (SEQ ID NO 2442)
ALL PYRIMIDINES = 2'-O-ME OR 2'-FLUORO EXCEPT POSITIONS (N N)

5'- B-N N N N N N N N N N N N N N N N N N N (N N)-B -3'
3'- L-(N_SN) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2443)
ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N)

D

SENSE STRAND (SEQ ID NO 2444)
ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N) AND ALL PURINES = 2'-DEOXY

5'- B-N N N N N N N N N N N N N N N N N N N (N N)-B -3'
3'- L-(N_SN) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2441)
ALL PYRIMIDINES = 2'-FLUORO AND ALL PURINES = 2'-O-ME EXCEPT POSITIONS (N N)

E

SENSE STRAND (SEQ ID NO 2445)
ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N)

5'- B-N N N N N N N N N N N N N N N N N N N (N N)-B -3'
3'- L-(N_SN) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2441)
ALL PYRIMIDINES = 2'-FLUORO AND ALL PURINES = 2'-O-ME EXCEPT POSITIONS (N N)

F

SENSE STRAND (SEQ ID NO 2444)
ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N) AND ALL PURINES = 2'-DEOXY

5'- B-N N N N N N N N N N N N N N N N N N N (N N)-B -3'
3'- L-(N_SN) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2446)
ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N) AND ALL PURINES = 2'-DEOXY

POSITIONS (NN) CAN COMPRISE ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES (eg. THYMIDINE) OR UNIVERSAL BASES
B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP THAT IS OPTIONALLY PRESENT
L = GLYCERYL MOIETY THAT IS OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE

Figure 5

A

SENSE STRAND (SEQ ID NO 2447)

5'- iB- U C U G A U G A U G U C A G A U A U G *T T*-iB -3'

3'- L-T_S*T* A G A C U A C U A C A G U C U A U A C -5'

ANTISENSE STRAND (SEQ ID NO 2448)

B

SENSE STRAND (SEQ ID NO 2449)

5'- *u c u g a u g a u g u c a g a u a u g* T_S*T* -3'

3'- L-T_S*T* a g a c u a c u a c a g u c u a u a c -5'

ANTISENSE STRAND (SEQ ID NO 2450)

C

SENSE STRAND (SEQ ID NO 2451)

5'- iB-u c u G A u G A u G u c A G A u A u G *T T*-iB -3'

3'- L-T_S*T* A G A *c u* A *c u* A *c* A G *u c u* A *u* A *c* -5'

ANTISENSE STRAND (SEQ ID NO 2452)

D

SENSE STRAND (SEQ ID NO 2453)

5'- iB-*u c u G A u G A u G u c A G A u A u G T T*-iB -3'

3'- L-T_S*T* a g a c u a c u a c a g u c u a u a c -5'

ANTISENSE STRAND (SEQ ID NO 2450)

E

SENSE STRAND (SEQ ID NO 2454)

5'- iB-*u c u* G A *u* G A *u* G *u c* A G A *u* A *u* G *T T*-iB -3'

3'- L-T_S*T* a g a c u a c u a c a g u c u a u a c -5'

ANTISENSE STRAND (SEQ ID NO 2450)

F

SENSE STRAND (SEQ ID NO 2453)

5'- iB-*u c u G A u G A u G u c A G A u A u G T T*-iB -3'

3'- L-T_S*T A G A c u A c u A c A G u c u A u A c* -5'

ANTISENSE STRAND (SEQ ID NO 2455)

lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro
italic lower case = 2'-deoxy-2'-fluoro
underline = 2'-O-methyl

ITALIC UPPER CASE = DEOXY
B = INVERTED DEOXYABASIC
L = GLYCERYL MOIETY OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE

Figure 6



Figure 7


A
5'- R1 NNNNNNNNNNNNNNNNNNN X X X X X
NNN
3'-EXTENSION
B
5'- R1 NNNNNNNNNNNNNNNNNNN X X X X X
3'- R2 NNNNNNNNNNNNNNNNNNN
MELT AND CLONE
C
5'- R1 NNNNNNNNNNNNNNNNNNXXXXNNNNNNNNNNNNNNNNNN R2 -3'
3'- PRIMER -5'
U6 snRNA PROMOTER
TERMINATION REGION
R1 = RESTRICTION SITE #1
R2 = RESTRICTION SITE #2
N = A, G, C, or T
X = A, G, C, or T LOOP SEQUENCE

Figure 8


A
5'- R1 NNNNNNNNNNNNNNNNNNNN R2 X X X
R2 X X X
3'-EXTENSION
B
5'- R1 NNNNNNNNNNNNNNNNNNNN R2 X X X
3'- R1 NNNNNNNNNNNNNNNNNNNN R2 X X X
CLEAVAGE WITH RESTRICTION ENZYMES 1 AND 2
C
5'- NNNNNNNNNNNNNNNNNNNN
3'- NNNNNNNNNNNNNNNNNNNN
CLONE
U6 snRNA PROMOTER
U6 snRNA PROMOTER
R1 = RESTRICTION SITE #1
R2 = RESTRCTION SITE #2
N = A, G, C, or T
X = A, G, C, or T

Figure 9: Target site Selection using siRNA



Figure 10



R = O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl
B = Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).

Figure 11: Modification Strategy





Figure 12: Inhibition of VEGF-Induced Angiogenesis by siRNAs

Figure 13: A375 24h 36B4 VEGFR1 mRNA Expression



Figure 14: Phosphorylated siNA constructs



Phosphates can be modified as described herein

Asymmetric hairpin siNA





Asymmetric duplex siNA

(n) = number of base pairs (e.g. 3-18 bp)

Figure 15: 5'-phosphate modifications



Figure 16: siNA Targeting VEGFR-1 Inhibits VEGF-Induced Rat Corneal Angiogenesis



Figure 17: Inhibition of Mouse CNV with anti-VEGFR-1 siNA (intraocular administration)



Figure 18: Inhibition of Mouse CNV with anti-VEGFR-1 siNA (periocular administration)



Figure 19: Inhibition of Mouse CNV with anti-VEGFR-1 siNA (periocular administration)